Previous close | 10.31 |
Open | 10.30 |
Bid | 10.28 x 50000 |
Ask | 10.40 x 50000 |
Day's range | 10.28 - 10.30 |
52-week range | 9.41 - 27.92 |
Volume | |
Avg. volume | 594 |
Market cap | 1.388B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.08 |
Earnings date | 29 Jul 2024 - 02 Aug 2024 |
Forward dividend & yield | 0.19 (1.81%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | 57.50 |
Amidst a buoyant U.S. market landscape, marked by the S&P 500 reaching an unprecedented high and dovish remarks from Federal Reserve Chairman Jerome Powell, small-cap stocks present unique opportunities for discerning investors. In this context, understanding the intrinsic qualities that define undervalued small-cap stocks becomes crucial to identifying potential investment gems.
Despite a flat performance over the last week, the United States stock market has seen an impressive 24% increase over the past year with earnings expected to grow by 15% annually. In such a thriving environment, undervalued small-cap stocks like AtriCure, which show promising insider actions, could present intriguing opportunities for investors looking for potential growth.
Amid a robust surge in the U.S. stock market, with major indices like the S&P 500 and Nasdaq 100 reaching new highs largely due to mega-cap tech companies, smaller cap stocks often present unique opportunities for discerning investors. Given the current economic climate and insider transactions, understanding what makes a small-cap stock potentially undervalued could be particularly timely.